Document is current
Any future updates will be listed below
-
Authors
Liu, Jiaxuan
Jiang, Mingxia
Zhang, Mengqi
Zhou, Shihan
Li, Mingxiao
Shi, Xiuqing
Li, Lixi
Yang, Xue
Li, Pei
Tian, Meng
Ma, Fei
Xu, Binghe
Li, Qiao
-
Funding
Funding for this research was provided by:
CAMS Innovation Fund for Medical Sciences (2023-I2M-C&T-B-096)
National High Level Hospital Clinical Research Funding (2025-LYZX-D-A02)
Noncommunicable Chronic Diseases-National Science and Technology Major Project (2025ZD0552504)
National Key Research and Development Program of China (2024YFA1107400)
Beijing Natural Science Foundation (L254037)
- License Information
-
More Information
Article History
Received: 8 February 2026
Accepted: 23 April 2026
First Online: 28 April 2026
Declarations
:
: The present study (protocol number: CSPC-DED-BC-K01) was approved by the Ethics Committee of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (Approval No. 23/123–3865) and was registered at clinicaltrials.gov (NCT06156761). The study was conducted in accordance with the criteria set by the Declaration of Helsinki. All patients voluntarily participated and provided written informed consent before the initiation of any study-related treatment or procedures.
: Not applicable.
: Pei Li and Meng Tian are employees of CSPC Ouyi Pharmaceutical Co., Ltd. The remaining authors declare that they have no competing interests.
